Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.70 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | SMO | Q99835 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6667710 | 0.96 | RAB9A (0.74) | RAB9ANPC1KCNK3KCNK9MEN1 | |
| SCHEMBL22305399 | 0.90 | KCNK3 (0.83) | RAB9ANPC1KCNK3KCNK9MEN1 | |
| SCHEMBL3794687 | 0.85 | NPC1 (1.00) | RAB9ANPC1KCNK3KCNK9MEN1 | |
| SCHEMBL5668018 | 0.84 | P2RX1 (0.80) | RAB9ANPC1KCNK3MAPT | |
| Iodide SCHEMBL30758613 | 0.84 | NPC1 (0.97) | RAB9ANPC1KCNK3KCNK9MEN1 | |
| SCHEMBL29984679 | 0.83 | NPC1 (0.72) | RAB9ANPC1KCNK3KCNK9MEN1 | |
| SCHEMBL197003 | 0.82 | MEN1 (0.73) | RAB9ANPC1MEN1KMT2ASIRT1 | |
| SCHEMBL25358559 | 0.82 | NPC1 (0.66) | RAB9ANPC1KCNK3KCNK9MEN1 | |
| SCHEMBL2298254 | 0.82 | KCNK3 (1.00) | RAB9ANPC1KCNK3KCNK9MEN1 | |
| SCHEMBL4341392 | 0.81 | NPC1 (0.70) | RAB9ANPC1KCNK3KCNK9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | RAB9A 1357/4885NPC1 724/4885KCNK3 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.